Company research / IKT
Inhibikase Therapeutics, Inc. (IKT)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2024-12-31, Inhibikase Therapeutics, Inc. reported revenue of $0. Revenue fell 100.0% from the prior annual period.
Key ratios (year ended 2024-12-31)
-29.0%
Return on year-end equity
-100.0%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.